✦ LIBER ✦

SAT-5-3 Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behavior

✍ Scribed by Neil C. Bodick; Walter Offen

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Xanomeline, a potent and specific M1 ago

✍ Pretzsch, Hans 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 123 KB

SAT-5-2 The discovery and pharmacology o

✍ H.E. Shannon; E.P. Bymaster; D.O. Calligaro; N.W. DeLapp; C.H. Mitch; J.S. Warc; 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 138 KB

182 The effects of xanomeline, an M1-sel

✍ N. Bodick; W. Offen; K. Rasmussen; S. Paul 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 122 KB

S-16-4 Xanomeline: The first study of th

✍ Neil C. Bodick; Walter Offen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 143 KB

41-5 - Transdermal delivery of xanomelin

✍ N.C. Bodick; R. Lucas; J.H. Satterwhite; W.W. Offen 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 429 KB

O3-04-06: Efficacy and tolerability of S

✍ Marina Zvartau-Hind; Gareth Maher-Edwards; Jackie Hunter; Michael Gold; Gillian 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB